The advent of recombinant growth hormone 20 years ago, which led to increased, albeit expensive, supplies of growth hormone (GH) in the market, has resulted in new treatments for short children. Apart from the 3 traditional indications to improve stature, namely (1) children with growth hormone deficiency, (2) Turner syndrome and (3) chronic renal failure, additional indications approved by the US Food and Drug Administration include children who are born small for gestational age, Prader Willi syndrome, and children with idiopathic short stature (ISS).
This article is available only as a PDF. Please click on “Download PDF” to view the full article.
